Trial Status |
Recruitement Closed |
Phase |
Phase II |
Type of cancer |
Pancreatic cancer |
Study design |
Two arm, comparative, randomized, crossover, open label, multicenter.
|
Objectives |
Primary
To compare quality of life scores and times to definitive deterioration in patients receiving nab-paclitaxel + gemcitabine versus gemcitabine alone using the EORTC QLQ-C30 questionnaire.
Secondary
To evaluate in both treatment Arms:
- Safety and tolerability profile (NCI-CTCAE v. 4.0)
- Overall response and duration of response as assessed by imaging (RECIST 1.1) and tumour markers
- Disease control rates
- Progression free survival (PFS) and overall survival (OS)
- Changes in serum CA 19-9 and CEA and composite index CA19-9xCEA
- Exploratory biomarker and hypoxia studies on blood products and tumour tissues with possible correlations with efficacy outcomes.
|
Inclusion Main criteria |
- Written informed consent (+ optional for TR) must be given according to ICH/GCP and national/local regulations.
- Patient is at least 18 years of age.
- Unresectable locally advanced or metastatic pancreatic cancer.
- Histologically or cytologically confirmed adenocarcinoma of the pancreas. Islet cell neoplasms and neuroendocrine tumours are excluded.
- Evaluable or measurable disease, not in a previously irradiated area.
- Life expectancy of at least 12 weeks.
- WHO ECOG performance status (PS) ≤ 2
- Adequate organ function.
- Adequate bone marrow, hepatic and renal function:
- Hemoglobin > 8.0 g/dL, absolute neutrophil count > 1.5 x 109/L, platelet count > 100 x 109/L
- ALAT, ASAT < 2.5 x ULN, up to < 5 x ULN in case of liver involvement
- Total bilirubin < 2 x ULN. No jaundice.
- Serum creatinine < 1.5 x ULN and /or calculated creatinine clearance
- Acceptable coagulation determined on routine tests (e.g. prothrombin time, partial thromboplastin time, INR, etc, within +/- 15% of normal limits or as per clinical practice).
- No clinically significant abnormalities in urinalysis.
- Effective contraception for both male and female patients if applicable.
Women of childbearing potential must have negative blood pregnancy test at screening visit.
|
Exclusion Main criteria |
- Prior chemotherapy, surgery or other investigational therapy for the treatment for metastatic disease. Adjuvant treatment with gemcitabine or 5-FU is allowed provided at least 6 months have elapsed since completion of the last dose.
- Major surgery within 4 weeks of the start of the study.
- Irradiation within 3 weeks prior to study entry.
- Brain metastasis (known or suspected).
- Serious medical risk factors involving any of the major organ systems, including high cardiovascular risk including coronary stenting or myocardial infarction in the last year and psychiatric disorders.
- Known infection with HIV or active infection with hepatitis B or C.
- History of connective tissue disorders (eg. lupus, scleroderma, arteritis nodosa, etc).
- History of interstitial lung disease.
- History of peripheral artery disease
- Previous (within 5 years) or concurrent malignancies at other sites with the exception of surgically cured or adequately treated carcinoma in-situ of the cervix and basal cell carcinoma of the skin.
- Known allergy or any other adverse reaction to any of the drugs or to any related compound.
- Use of oral anticoagulants that interfere with the metabolic path of nab- Paclitaxel (cytochrome P450 isoenzymes CYP2C8 and CYP3A4) such as warfarin (Coumadin), rivaroxaban (Xarelto), etc, and the impossibility to switch anticoagulation treatment to low molecular weight heparin.
- Organ allografts requiring immunosuppressive therapy.
- Pregnancy or breast-feeding.
- Medical, social or psychological condition which, in the opinion of the investigator, would not permit the patient to complete the study or sign meaningful informed consent.
|
Treatment schedule |
Patients will be randomized to receive nab-paclitaxel + gemcitabine or gemcitabine alone
|
Study Period |
Study period: end recruitment: Oct 2015
|
Study Coordinators |
U.Z. Leuven (University Hospital Leuven) Digestive Oncology Unit
|
Participating Groups |
|
Participating centres |
UZ Leuven; AZ Delta - Campus Wilgenstraat Roeselare; AZ Klina - Brasschaat; AZ Maria Middelares Gent; AZ Sint Maarten Mechelen; AZ St-Lucas Brugge; AZ Turnhout - Campus St-Elisabeth; CHC St-Joseph Liege; CHR Citadelle Liege; CHU de Charleroi - Site Vésale; CHU Sart-Tilman Liege; Clinique Ste-Elisabeth Namur; Cliniques Universitaires Saint Luc BXL; HHZH Lier; Hôpital Erasme; OLV Ziekenhuis Aalst; UZ Antwerpen; UZ Gent;
|
Protocol summary |
https://clinicaltrials.gov/ct2/show/NCT02106884?term=qolinpac&rank=1 |
NCT number |
NCT02106884 |
EudraCT |
2013-004101- 75 |
Interest to participate |
clinicaltrials@bgdo.org |
More info |
clinicaltrials@bgdo.org |